Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an automatic tax-related share sale. The company sold 844 shares of common stock on his behalf at an average price of $515.90 per share to cover tax withholding obligations from vesting restricted stock units. After this transaction, he directly holds 11,075 shares, and the sale was not made at his discretion.
MDGL submitted a Rule 144 notice to sell 844 shares of Common Stock following a Restricted Stock Unit Grant that vested on 05/15/2026. The transaction is listed with Morgan Stanley Smith Barney LLC as broker and the filing date shown is 05/18/2026.
Madrigal Pharmaceuticals: Paulson & Co. Inc. amended a Schedule 13G to report beneficial ownership of 1,392,188 shares of Common Stock, representing 6.1% of the class. The filing cites 22,939,969 shares outstanding as of February 12, 2026. Paulson states the shares are owned by its advisory Funds and disclaims beneficial ownership while asserting voting and dispositive power over those Fund holdings.
Madrigal Pharmaceuticals ownership disclosure: Janus Henderson Group plc reports beneficial ownership of 2,018,647 shares of Madrigal Pharmaceuticals common stock, representing 8.8% of the class as reported. The filing states the position reflects shared voting and dispositive power across Janus Henderson asset managers.
The filing clarifies the Asset Managers exercise voting discretion for Managed Portfolios and disclaim rights to receive dividends or sale proceeds tied to those Managed Portfolios; specific subsidiaries and exhibits are referenced for further identification.
Madrigal Pharmaceuticals reported strong early commercialization of Rezdiffra in its quarterly results while remaining loss-making. For the three months ended March 31, 2026, product revenue, net reached $311.3 million, up from $137.3 million a year earlier, driven by U.S. and initial European launches.
Total operating expenses rose to $404.1 million, reflecting higher research and development spending of $108.7 million and selling, general and administrative costs of $268.5 million to support commercialization and pipeline growth. The company recorded a net loss of $94.4 million, or $3.25 per share, compared with a $73.2 million loss in the prior-year quarter.
Madrigal ended the period with $817.9 million in cash, cash equivalents, restricted cash and marketable securities and $350.0 million of outstanding principal under its term loan facility. The company expanded its MASH-focused pipeline through licensing deals for a GLP‑1 agonist, a DGAT‑2 inhibitor and multiple siRNA programs targeting genetic drivers of disease.
Madrigal Pharmaceuticals reported strong first-quarter 2026 growth driven by its MASH drug Rezdiffra. Net revenues reached $311.3 million, up 127% from $137.3 million a year earlier, reflecting broad physician adoption and high patient demand.
Operating expenses rose to $404.1 million, including $54.3 million of one-time business development costs and $34.0 million of non-cash stock-based compensation. The company reported a net loss of $94.4 million, or $3.25 per share, compared with a $73.2 million loss in the prior-year quarter.
Madrigal ended March 31, 2026 with $817.9 million in cash, cash equivalents, restricted cash and marketable securities. More than 42,250 patients were on Rezdiffra as of March 31, 2026, and management highlighted that Rezdiffra has achieved blockbuster status on a trailing 12‑month net sales basis.
Madrigal Pharmaceuticals, Inc. reported a change in how its Board of Directors is classified, without changing who serves on the Board. On April 22, 2026, the Board rebalanced the membership of its three director classes so each class will be as evenly sized as possible after the 2026 Annual Meeting of Stockholders on June 17, 2026.
To accomplish this, Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, whose terms expire at the 2026 Annual Meeting. Each resigned from his prior Class III and Class II seat, respectively, solely to allow simultaneous reappointment as a Class I director, and their Board service is considered uninterrupted. Their committee assignments did not change, and both, along with James Daly, have been nominated for re-election at the 2026 Annual Meeting.
Madrigal Pharmaceuticals calls a virtual 2026 annual meeting on June 17 to elect three Class I directors, hold an advisory vote on executive pay, ratify PwC as auditor, and seek approval of a new 2026 Stock Plan and 2026 Employee Stock Purchase Plan.
The company highlights a breakout first commercial year for MASH drug Rezdiffra, with 2025 net revenue of $958.4 million, up sharply from 2024, and more than 36,250 patients on therapy by year-end. Management reports Rezdiffra sales running at over $1 billion on an annualized quarterly basis and notes new patent protection expected into 2045, along with expansion into Germany and development of more than ten complementary MASH programs.
The proxy emphasizes strong stockholder alignment, including a prior say‑on‑pay approval of about 99%, pay-for-performance design with a heavy mix of at-risk equity (options, RSUs and PSUs tied to relative total stockholder return), and standard governance practices such as an independent chair, fully independent key committees and robust insider trading, hedging and pledging restrictions.